PT  - JOURNAL ARTICLE
AU  - Christian Boch
AU  - Jens Kollmeier
AU  - Andreas Roth
AU  - Daniel Misch
AU  - Anna Streubel
AU  - Thomas Mairinger
AU  - Torsten T. Bauer
TI  - One year survival differences of EGFR- and KRAS-mutated advanced non-small cell lung cancer (NSCLC) compared to the wildtype population
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - P4181
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/P4181.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/P4181.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - Introduction: With investigation of the complex relationship between EGFR-related biomarkers and response to tyrosine kinase inhibitor (TKI) novel therapies for NSCLC have been established. In numerous clinical studies the effect of TKIs in patients with activating EGFR mutations is proven by a better progression free survival (PFS) while the prognostic value of KRAS mutations remain vague. The current study in our clinic retrospectively analysed the one year survival of patients with NSCLC and an activating EGFR- or KRAS-mutation.Methods: Within 15 months until Dec 2010, all subsequent biopsies of newly diagnosed NSCLC (n=753) were tested for the ability to be analysed by Sanger- and Pyrosequencing for the presence of EGFR mutations and by LightCycler Real-time PCR for the presence of KRAS mutations. The obtained data were correlated with the centre-bound tumour registry for survival data and analysed by Kaplan-Meier estimator.Results: In a total of 552 cases with NSCLC, EGFR mutation was present in 27/552 (4,9%, male n=10) and KRAS mutation in 85/552 cases (15,8%, male n=43). In advanced NSCLC (IIIB/IV), 16/27 patients had an EGFR mutation and 46/85 had KRAS mutation. The one year survival of advanced NSCLC and EGFR mutation was 11/16 (68,8%) vs. 5/16 (31,3%) without mutation. Stratifying according to KRAS it was 15/46 (34,8%) with vs. 30/46 (65,2%) without mutation.Conclusion: Comparable with previous reports, the one year survival of NSCLC with EGFR mutation is improved whereas the the one year survival with KRAS mutations seems to be poorer.